| Keywords: |
treatment response; unclassified drug; clinical trial; drug tolerability; fatigue; doxorubicin; cancer combination chemotherapy; drug efficacy; drug safety; monotherapy; side effect; drug approval; liver dysfunction; note; capecitabine; paclitaxel; disease free survival; gene overexpression; carboplatin; metastasis; progression free survival; breast cancer; gene expression; antineoplastic combined chemotherapy protocols; epidermal growth factor receptor; epidermal growth factor receptor 2; cyclophosphamide; breast neoplasms; cancer resistance; docetaxel; protein tyrosine kinase inhibitor; protein kinase inhibitors; antibodies, monoclonal; drug mechanism; clinical trials, phase iii as topic; thrombocyte count; heat shock protein 90 inhibitor; tanespimycin; hsp90 heat-shock proteins; receptor, erbb-2; taxane derivative; trastuzumab; navelbine; anthracycline; quinazolines; lapatinib; maytansine; neratinib; pertuzumab; 4 [3 chloro 4 (2 pyridinylmethoxy)anilino] 3 cyano 6 (4 dimethylaminocrotonamido) 7 ethoxyquinoline
|
